Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Pharmacy Chain 36.6 reported for 9 months of 2023 by RAS

10/27/23 APTK

Rosseti Kuban reported for 9 months of 2023 by RAS

10/27/23 KUBE

TGC-2 reported for 9 months of 2023 by RAS

10/27/23 TGKB

Sanofi reported for 9 months of 2023

10/27/23 SNY

Yakutskenergo reported for 9 months of 2023 by RAS

10/27/23 YKEN

Magadanenergo reported for 9 months of 2023 by RAS

10/27/23 MAGE

DEK reported for 9 months of 2023 by RAS

10/27/23 DVEC

Sakhalinenergo reported for 9 months of 2023 by RAS

10/27/23 SLEN

Ford reported for 9 months of 2023

10/27/23 F

Amazon reported for 9 months of 2022

10/27/23 AMZN